Total Payments
$20,685
2024 Payments
$5,240
Companies
79
Transactions
908
Medicare Patients
6,701
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$20,455 (98.9%)
Education$229.91 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,455 | 901 | 98.9% |
| Education | $229.91 | 7 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,373 | 60 | $0 (2024) |
| PFIZER INC. | $1,315 | 69 | $0 (2024) |
| Janssen Biotech, Inc. | $1,096 | 38 | $0 (2024) |
| Merck Sharp & Dohme LLC | $999.01 | 43 | $0 (2024) |
| Genentech USA, Inc. | $855.33 | 47 | $0 (2024) |
| Amgen Inc. | $791.75 | 37 | $0 (2023) |
| GlaxoSmithKline, LLC. | $739.70 | 30 | $0 (2024) |
| Celgene Corporation | $694.76 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $693.42 | 36 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $683.47 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,240 | 215 | AstraZeneca Pharmaceuticals LP ($596.57) |
| 2023 | $5,697 | 241 | PFIZER INC. ($484.79) |
| 2022 | $3,976 | 176 | Exelixis Inc. ($345.23) |
| 2021 | $1,388 | 61 | Amgen Inc. ($258.12) |
| 2020 | $1,817 | 91 | PFIZER INC. ($185.90) |
| 2019 | $2,353 | 113 | Genentech USA, Inc. ($303.11) |
| 2018 | $212.83 | 11 | Seattle Genetics, Inc. ($41.49) |
All Payment Transactions
908 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.93 | General |
| 12/18/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Oncology | ||||||
| 12/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $27.09 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/13/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $28.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.29 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $31.41 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.14 | General |
| 11/27/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $22.39 | General |
| 11/25/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 11/22/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $31.27 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.77 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 2,300 | 26,394 | $1.9M | $467,924 |
| 2022 | 31 | 1,822 | 13,806 | $1.5M | $468,857 |
| 2021 | 22 | 1,467 | 27,820 | $822,639 | $380,842 |
| 2020 | 19 | 1,112 | 10,677 | $597,814 | $270,112 |
Total Patients
6,701
Total Services
78,697
Medicare Billing
$1.6M
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 381 | 1,087 | $456,085 | $110,498 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 202 | 484 | $285,725 | $72,594 | 25.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 555 | $259,296 | $64,935 | 25.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 23 | 2,742 | $195,927 | $51,210 | 26.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 138 | 388 | $144,024 | $38,680 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 216 | 420 | $124,566 | $28,359 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 109 | 109 | $78,477 | $19,642 | 25.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 111 | 119 | $67,901 | $17,072 | 25.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 57 | 533 | $53,957 | $13,525 | 25.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 204 | $46,653 | $12,015 | 25.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 138 | $31,353 | $7,534 | 24.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 65 | 446 | $21,287 | $5,275 | 24.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 36 | 188 | $18,496 | $4,709 | 25.5% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 26 | 128 | $14,772 | $3,693 | 25.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 117 | $13,738 | $3,392 | 24.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 429 | 738 | $12,288 | $3,067 | 25.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 63 | $11,510 | $3,003 | 26.1% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 46 | $9,004 | $2,282 | 25.3% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 28 | 163 | $7,166 | $1,853 | 25.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $6,024 | $1,360 | 22.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 40 | 1,129 | $2,775 | $737.21 | 26.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 29 | 197 | $2,149 | $578.29 | 26.9% |
| J9263 | Injection, oxaliplatin, 0.5 mg | Office | 2023 | 12 | 7,621 | $1,551 | $424.52 | 27.4% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 11 | 3,486 | $1,500 | $386.43 | 25.8% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 34 | 300 | $1,161 | $299.53 | 25.8% |
About Dr. Weber Chen, M.D
Dr. Weber Chen, M.D is a Specialist healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679504393.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Weber Chen, M.D has received a total of $20,685 in payments from pharmaceutical and medical device companies, with $5,240 received in 2024. These payments were reported across 908 transactions from 79 companies. The most common payment nature is "Food and Beverage" ($20,455).
As a Medicare-enrolled provider, Chen has provided services to 6,701 Medicare beneficiaries, totaling 78,697 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location Pasadena, CA
- Active Since 07/05/2006
- Last Updated 07/21/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1679504393
Products in Payments
- KEYTRUDA (Biological) $961.43
- ORGOVYX (Drug) $512.28
- LYNPARZA (Drug) $493.41
- IBRANCE (Drug) $451.94
- ERLEADA (Drug) $416.56
- GILOTRIF (Drug) $411.22
- ZEJULA (Drug) $409.19
- LIBTAYO (Biological) $407.18
- VERZENIO (Drug) $406.20
- OPDIVO (Biological) $398.99
- XALKORI (Drug) $362.04
- Lenvima (Drug) $354.03
- XTANDI (Drug) $346.90
- LUMAKRAS (Drug) $345.72
- Cabometyx (Drug) $345.23
- DARZALEX (Biological) $343.50
- XPOVIO (Drug) $340.29
- SARCLISA (Biological) $338.02
- Trodelvy (Drug) $328.69
- JAKAFI (Drug) $327.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Pasadena
Michael Gottlieb, Md, MD
Specialist — Payments: $404,659
Specialist $404,659
Dr. Nima Naghshineh, M.d, M.D
Specialist — Payments: $89,341
Specialist $89,341
Dr. Jason Boutros, M.d, M.D
Specialist — Payments: $22,861
Specialist $22,861
Stephen Huang, M.d, M.D
Specialist — Payments: $13,903
Specialist $13,903
Dr. Robert Seltzer, M.d, M.D
Specialist — Payments: $11,996
Specialist $11,996
Dr. Gabriel Pai, M.d, M.D
Specialist — Payments: $9,402
Specialist $9,402